AN-018
Neurodegenerative Diseases (Alzheimer's, Parkinson's) and Methamphetamine Addiction
PreclinicalActive
Key Facts
Indication
Neurodegenerative Diseases (Alzheimer's, Parkinson's) and Methamphetamine Addiction
Phase
Preclinical
Status
Active
Company
About Accuitis
Accuitis is a private, preclinical biotech founded in 2015 and based in San Diego, California. The company is advancing a novel therapeutic approach centered on restoring mitochondrial health via SIRT3 activation to address neurodegenerative diseases. Its lead asset, AN-018, has undergone extensive preclinical validation but has not yet entered clinical trials. The company operates as a pre-revenue entity, likely funded by private investment, and faces the significant challenges of translating its platform into clinical success.
View full company profile